Holen Sie sich die Stockscreener-App
94.29
0.61%
-0.58
Handel nachbörslich:
94.29
Schlusskurs vom Vortag:
$94.87
Offen:
$93.79
24-Stunden-Volumen:
1.15M
Relative Volume:
1.12
Marktkapitalisierung:
$5.39B
Einnahmen:
$360.35M
Nettoeinkommen (Verlust:
$-149.57M
KGV:
-31.85
EPS:
-2.96
Netto-Cashflow:
$-81.27M
1W Leistung:
-1.80%
1M Leistung:
+0.49%
6M Leistung:
-34.36%
1J Leistung:
-14.82%
1-Tages-Spanne:
$91.97
$95.14
1-Wochen-Bereich:
$91.97
$101.57
52-Wochen-Spanne:
$77.10
$163.71
Glaukos Corporation Stock (GKOS) Company Profile
Firmenname
Glaukos Corporation
Sektor
Branche
Telefon
949-367-9600
Adresse
1 GLAUKOS WAY, ALISO VIEJO, CA
Vergleichen Sie GKOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corporation
|
94.29 | 5.49B | 360.35M | -149.57M | -81.27M | -2.96 |
|
ABT
Abbott Laboratories
|
133.58 | 228.44B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
105.26 | 154.60B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
382.64 | 143.93B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
82.98 | 103.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.22 | 43.99B | 5.54B | 4.18B | 623.10M | 7.00 |
Glaukos Corporation Stock (GKOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-12-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-12-06 | Eingeleitet | UBS | Buy |
| 2024-12-02 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-12-04 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-11-28 | Eingeleitet | Truist | Buy |
| 2023-11-08 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | Eingeleitet | Mizuho | Neutral |
| 2022-12-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-10-14 | Fortgesetzt | Stephens | Overweight |
| 2022-10-04 | Eingeleitet | Needham | Buy |
| 2022-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2022-02-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | Hochstufung | BTIG Research | Neutral → Buy |
| 2021-11-03 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-07-14 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | Hochstufung | Citigroup | Sell → Neutral |
| 2020-12-09 | Eingeleitet | Oppenheimer | Perform |
| 2020-11-17 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-06-15 | Eingeleitet | Jefferies | Hold |
| 2020-03-05 | Eingeleitet | Citigroup | Sell |
| 2020-02-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-01-06 | Hochstufung | Berenberg | Hold → Buy |
| 2019-12-12 | Herabstufung | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | Eingeleitet | BTIG Research | Neutral |
| 2018-08-30 | Eingeleitet | Berenberg | Hold |
| 2018-08-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-08-03 | Bestätigt | Stifel | Hold |
| 2018-06-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-04-13 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-01 | Bestätigt | Cantor Fitzgerald | Buy |
| 2017-03-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-01-06 | Hochstufung | Stifel | Hold → Buy |
| 2016-10-27 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Glaukos Corporation Aktie (GKOS) Neueste Nachrichten
Those who invested in Glaukos (NYSE:GKOS) three years ago are up 120% - Yahoo
Glaukos at Stifel Forum: iDose Launch and Strategic Outlook By Investing.com - Investing.com India
Glaukos at Stifel Forum: iDose Launch and Strategic Outlook - Investing.com Australia
Glaukos Corp (GKOS) Shares Up 3.69% on May 27 - GuruFocus
Glaukos Corporation (NYSE:GKOS) Q1 2025 Earnings Call Transcript - MSN
Here's Why You Should Retain Glaukos Stock in Your Portfolio - MSN
BNP Paribas Financial Markets Trims Stock Holdings in Glaukos Co. (NYSE:GKOS) - Defense World
Those who invested in Glaukos (NYSE:GKOS) five years ago are up 156% - simplywall.st
Alex Thurman: Dealing with Too Bullish Investors - Orange County Business Journal
Glaukos Corp (GKOS) Trading 3.06% Higher on May 16 - GuruFocus
Tiny Tech, Big Impact: Glaukos Team Automates Vision-Saving Implants - University of San Diego
Research Analysts’ Recent Ratings Changes for Glaukos (GKOS) - Defense World
Glaukos Releases Its 2024 Sustainability Report - VisionMonday.com
Glaukos Highlights Innovation in May 2025 Presentation - TipRanks
Glaukos Announces Participation in Upcoming Investor ConferencesMay 13, 2025 - BioSpace
(GKOS) Trading Signals - news.stocktradersdaily.com
Glaukos Corporation (GKOS) Fell as its iDose Results Fell Short of Expectations - Insider Monkey
Hsbc Holdings PLC Decreases Position in Glaukos Co. (NYSE:GKOS) - Defense World
Interesting GKOS Put And Call Options For August 15th - Nasdaq
Glaukos (GKOS) Analyst Rating Update: Price Target Revised Downw - GuruFocus
What is William Blair’s Estimate for Glaukos Q1 Earnings? - Defense World
Stephens Issues Pessimistic Forecast for Glaukos (NYSE:GKOS) Stock Price - Defense World
Glaukos projects 2025 sales in the $475M-$485M range with strong iDose ramp - MSN
Glaukos (NYSE:GKOS) Stock Rating Lowered by Wells Fargo & Company - Defense World
Decoding Glaukos Corp (GKOS): A Strategic SWOT Insight - GuruFocus
Stephens cuts Glaukos stock price target to $115 from $140 By Investing.com - Investing.com South Africa
What 11 Analyst Ratings Have To Say About Glaukos - Benzinga
GKOS: Stephens & Co. Lowers Price Target for Glaukos to $115 | G - GuruFocus
Stephens cuts Glaukos stock price target to $115 from $140 - Investing.com
Glaukos (GKOS) Price Target Reduced by Stephens Following Earnin - GuruFocus
Glaukos (GKOS) Price Target Reduced by Stephens Following Earnings Report | GKOS Stock News - GuruFocus
Glaukos First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline - MSN
How To Trade (GKOS) - news.stocktradersdaily.com
Glaukos Corp. Reports Record Revenue and Growth - TipRanks
Glaukos (GKOS) Sees Price Target Reduction by Stifel Analyst | G - GuruFocus
Needham cuts Glaukos stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
JPMorgan cuts Glaukos stock target to $100 from $160 By Investing.com - Investing.com Nigeria
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
Needham cuts Glaukos stock price target to $115, maintains Buy - Investing.com Australia
Glaukos (GKOS) Price Target Revised Down to $135 by Truist Securities | GKOS Stock News - GuruFocus
Finanzdaten der Glaukos Corporation-Aktie (GKOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):